Search research articles
Contact Us
Filters
Showing results (61-70 of 92) with videos related to
Page
of 10
Sort By:
ACS Omega
|
October 9, 2023
Overcoming Challenges in Chemical Glycosylation to Achieve Innovative Vaccine Adjuvants Possessing Enhanced TLR4 Activity
Alessio Romerio, Ana Rita Franco, Melanie Shadrick, et al.
Frontiers in Pharmacology
|
May 23, 2022
Green and Roasted Coffee Extracts Inhibit Interferon-β Release in LPS-Stimulated Human Macrophages
Valentina Artusa, Carlotta Ciaramelli, Alessia D'Aloia, et al.
RSC Medicinal Chemistry
|
March 24, 2025
Towards more efficient synthetic immunomodulators: biological characterization and mechanism of action of monosaccharide-derived TLR4 agonists
Ana Rita Franco, Zaineh Aladailleh, Alessio Romerio, et al.
Chembiochem : a European Journal of Chemical Biology
|
March 29, 2014
Functional characterization of E. coli LptC: interaction with LPS and a synthetic ligand
Stefania E Sestito, Paola Sperandeo, Carlo Santambrogio, et al.
Alzheimer'S Research & Therapy
|
October 20, 2023
A small-molecule TLR4 antagonist reduced neuroinflammation in female E4FAD mice
Deebika Balu, Ana C Valencia-Olvera, Austin Nguyen, et al.
Chemical Biology & Drug Design
|
February 21, 2016
Glycolipid-based TLR4 Modulators and Fluorescent Probes: Rational Design, Synthesis, and Biological Properties
Carlotta Ciaramelli, Valentina Calabrese, Stefania E Sestito, et al.
Plos Pathogens
|
March 14, 2012
Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity
Annalisa Bianco, Veronica Reghellin, Lorena Donnici, et al.
Talanta
|
April 27, 2024
Vibrational spectroscopy coupled with machine learning sheds light on the cellular effects induced by rationally designed TLR4 agonists
Diletta Ami, Ana Rita Franco, Valentina Artusa, et al.
Journal of Medicinal Chemistry
|
December 8, 2024
Development of a New Vaccine Adjuvant System Based on the Combination of the Synthetic TLR4 Agonist FP20 and a Synthetic QS-21 Variant
Mohammed Monsoor Shaik, Samuel Pasco, Alessio Romerio, et al.
ACS Infectious Diseases
|
March 25, 2025
Monosaccharide-Based Synthetic TLR4 Agonist Enhances Vaccine Efficacy against <i>Pseudomonas aeruginosa</i> Challenge
Maite Sainz-Mejías, Chaoying Ma, Yueran Hou, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 92) with videos related to
Sort By:
Page
of 10
ACS Omega
|
October 9, 2023
Overcoming Challenges in Chemical Glycosylation to Achieve Innovative Vaccine Adjuvants Possessing Enhanced TLR4 Activity
Alessio Romerio, Ana Rita Franco, Melanie Shadrick, et al.
Frontiers in Pharmacology
|
May 23, 2022
Green and Roasted Coffee Extracts Inhibit Interferon-β Release in LPS-Stimulated Human Macrophages
Valentina Artusa, Carlotta Ciaramelli, Alessia D'Aloia, et al.
RSC Medicinal Chemistry
|
March 24, 2025
Towards more efficient synthetic immunomodulators: biological characterization and mechanism of action of monosaccharide-derived TLR4 agonists
Ana Rita Franco, Zaineh Aladailleh, Alessio Romerio, et al.
Chembiochem : a European Journal of Chemical Biology
|
March 29, 2014
Functional characterization of E. coli LptC: interaction with LPS and a synthetic ligand
Stefania E Sestito, Paola Sperandeo, Carlo Santambrogio, et al.
Alzheimer'S Research & Therapy
|
October 20, 2023
A small-molecule TLR4 antagonist reduced neuroinflammation in female E4FAD mice
Deebika Balu, Ana C Valencia-Olvera, Austin Nguyen, et al.
Chemical Biology & Drug Design
|
February 21, 2016
Glycolipid-based TLR4 Modulators and Fluorescent Probes: Rational Design, Synthesis, and Biological Properties
Carlotta Ciaramelli, Valentina Calabrese, Stefania E Sestito, et al.
Plos Pathogens
|
March 14, 2012
Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity
Annalisa Bianco, Veronica Reghellin, Lorena Donnici, et al.
Talanta
|
April 27, 2024
Vibrational spectroscopy coupled with machine learning sheds light on the cellular effects induced by rationally designed TLR4 agonists
Diletta Ami, Ana Rita Franco, Valentina Artusa, et al.
Journal of Medicinal Chemistry
|
December 8, 2024
Development of a New Vaccine Adjuvant System Based on the Combination of the Synthetic TLR4 Agonist FP20 and a Synthetic QS-21 Variant
Mohammed Monsoor Shaik, Samuel Pasco, Alessio Romerio, et al.
ACS Infectious Diseases
|
March 25, 2025
Monosaccharide-Based Synthetic TLR4 Agonist Enhances Vaccine Efficacy against <i>Pseudomonas aeruginosa</i> Challenge
Maite Sainz-Mejías, Chaoying Ma, Yueran Hou, et al.
Page
of 10